MSC is a novel 24 miRNA-test designed to help determine whether lung nodules are benign or malignant.

Data published from multiple prospective, randomized clinical trials demonstrate the ability of MSC to stratify patients with and without lung nodules according to their lung cancer risk. Utilization of our proprietary blood-based test in combination with LDCT could help triage patients for care more effectively and decrease costs to the healthcare system by reducing false positives with LDCT alone by a factor of five.¹

miRNA Biomarkers

MicroRNAs (miRNAs), which are present in many bodily fluids and thus accessible via minimally invasive procedures, offer significant potential as biomarkers for early cancer detection and improved patient outcomes.²

miRNA Signatures

The limitations of LDCT necessitate the use of additional tools to appropriately manage those at risk of lung cancer. The MSC miRNA test was designed for use with LDCT to more accurately stratify patients according to their risk of lung cancer.³

Annals of Oncology

This analysis of the BioMILD cohort demonstrated that MSC+ patients are at significantly higher risk of having or developing lung cancer than MSC- patients, regardless of the presence of a lung nodule.⁴

The Lancet Regional Health

This analysis of patients diagnosed with lung nodules demonstrated that MSC+ patients are more than 4x as likely to have or develop lung cancer as compared to MSC- patients.⁵

StemPrintER

Our proprietary test leveraging stem cell biology to predict cancer recurrence risk.

News

Get the latest press releases and company updates from AccuStem.

References: 1) Sozzi, et al. J Clin Oncol. 2014; 2) Metcalf, G. Oncogene. 2024; 3) Boeri, et al. Proc Natl Acad Sci. 2010; 4) Pastorino, et al. Ann Oncol. 2022; 5) Boeri, et al. Lancet Reg Health Eur. 2024